Sharemaestro Newsreel

Valneva GAAP EPS of -€0.35, revenue of €65.84M; reaffirms FY 2026

* Valneva press release [https://seekingalpha.com/pr/20617691-valneva-reports-half-year-2026-financial-results-and-provides-corporate-updates] (VALN [https://seekingalpha.com/symbol/VALN]): 1H GAAP EPS of -€0.35. * Revenue of €65.84M (-32.5% Y/Y). * Solid cash position of €121.5 million as of end June 2026. * FINANCIAL OUTLOOK * Despite the continued adverse impact of the geopolitical environment on …

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

VALNEVA SE Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with …

VERTEX PHARMACEUTICALS AKTIE: AI-Analysen, Prognose & Kursziel

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in Silver …

Formycon: Umsatz im ersten Halbjahr 2026 fast verdreifacht, Verluste deutlich reduziert

One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was …

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Vertex Pharmaceuticals' second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue …

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of …

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index …

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

The pharmaceutical sector differs from many industries as stock performance often depends less on near-term results and more on the success of products in development. For biotech companies, clinical and regulatory developments can sharply alter valuations by changing expectations for a drug's safety, efficacy …

Vertex Pharmaceuticals Rose 7% Today. Here’s Where the Stock Is Headed in 2026

Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low

The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals. Continue Reading

Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails

This article first appeared on GuruFocus. Vertex Pharmaceuticals (NASDAQ:VRTX), the biotech king of cystic fibrosis, jumped approximately 5.9% in Monday's regular session after a rival drug stumbled. Sionna Therapeutics said SION-719 missed the key activity endpoint in a Phase 2a trial when added to …

Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?

Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a …

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. Continue Reading

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover …

Regeneron Pharmaceuticals Inc (REGN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing …

SA Asks: What's the outlook for Big Pharma M&A?

[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a …

Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week

Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] …

Vertex Pharmaceuticals’ Q2 Earnings Call Confirmed an $8.8 Billion Bet. Here’s What That Means for the Stock

Vertex Pharmaceuticals Incorporated erhöht Gewinnprognose für das Gesamtjahr 2026

Regeneron Pharma Q2 Earnings: EYLEA HD Outsold EYLEA for the First Time

Vertex Pharmaceuticals: Bereinigter Gewinn und Umsatz im 2. Quartal steigen; Prognose für 2026 angehoben

VRTX|Vertex Pharmaceuticals Inc|Kurs:496.070|Änderung %:+12.040

Vertex hebt FY26-Umsatzprognose nach Q2-Ergebnis: Crinetics-Deal, ALYF

Die Allianz zwischen Vertex und AbCellera im Bereich T-Zell-Engager könnte die Argumente für eine Investition in Vertex Pharmaceuticals (VRTX) verändern

Heidelberg Pharma verringert Halbjahresverlust - finanziert bis Mitte 2027

EQS-News: Heidelberg Pharma berichtet über das erste Halbjahr 2026 und positiven Geschäftsverlauf - boerse.de

HPHA Prognose — Kursziel für 2027

Formycon Aktie: Umsatz verdreifacht, Ziel bestätigt

Formycon verdreifacht Umsatz – EBITDA-Verlust schrumpft deutlich